

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

THIS PAGE BLANK (USPTO)



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: A61K 31/00, 31/40, 38/55	A1	(11) International Publication Number: WO 99/36062 (43) International Publication Date: 22 July 1999 (22.07.99)
(21) International Application Number: PCT/US98/27183 (22) International Filing Date: 21 December 1998 (21.12.98) (30) Priority Data: 60/071,714 16 January 1998 (16.01.98) US (71) Applicant (for all designated States except US): ALCON LABORATORIES, INC. [US/US]; 6201 South Freeway, Fort Worth, TX 76134-2099 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): LANG, John, C. [US/US]; 2106 Riverfront Drive, Arlington, TX 76017 (US). BERGAMINI, Michael, V., W. [US/US]; 212 Briar Haven Court, Burleson, TX 76028 (US). (74) Agents: YEAGER, Sally, S. et al.; Alcon Laboratories, Inc., R & D Counsel Q-148, 6201 South Freeway, Fort Worth, TX 76134-2099 (US).		(81) Designated States: AU, BR, CA, JP, MX, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: TOPICAL ADMINISTRATION OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS (57) Abstract Topical ocular compositions comprising an angiotensin-converting enzyme inhibitor and methods for treating the retinopathy, neuropathy, and nephropathy associated with diabetes are disclosed.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Larvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

TOPICAL ADMINISTRATION OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS

5 The present invention is directed to the topical ocular administration of
angiotensin-converting enzyme (ACE) inhibitors for the treatment of diabetic neuropathy
and/or nephropathy and diabetic retinopathy.

Background of the Invention

10 There is extensive literature regarding the use of ACE inhibitors for the treatment
of persons suffering from type I diabetes, that is, insulin dependent diabetes mellitus.
Taguma, et al., "Effect of captopril on heavy proteinuria in azotemic diabetics," *N. Eng.
J. Med.*, 313, 1617-1620 (1985); Marre, et al., "Converting enzyme and kidney function
in normotensive diabetic patients with persistent microalbuminuria," *Br. Med. J.*, 294,
15 1448-1452 (1987); Brichard, et al., "Renal function, glycemic control and perindopril in
diabetic patients," *Clin. Exp. Theory Pract.*, A11 (Suppl 2), 545-554 (1989); Rudberg, et
al., "Enalapril reduces microalbuminuria in young normotensive type I (insulin-
dependent) diabetic patients irrespective of its hypotensive effect," *Diabetologia*, 33,
470-476 (1990); Mathiesen, et al., "Efficacy of captoprilin postponing nephropathy in
20 normotensive insulin dependent diabetic patients with microalbuminuria," *BMJ*, 303,
81-87 (1991); and Wiegmann, et al., "Effect of angiotensin-converting enzyme inhibition
on renal function and albuminuria in normotensive type I diabetic patients," *Diabetes*,
41, 62-67 (1992). The use of these compounds is believed to be involved in preventing
the nephropathy associated with type I diabetes.

25

Further research has indicated the possibility that ACE inhibitors might have a
role in treating diabetic retinopathy. In a two year trial with sixteen patients with type I
diabetes, early diabetic nephropathy, and normal blood pressures, systemic
administration of the ACE inhibitor, captopril, was shown to decrease retinal
30 deterioration. Jackson, et al., "Angiotensin-converting enzyme inhibitor therapy and
diabetic retinopathy," *Ann. Ophth* 24, 99-103 (1992). In a more extensive study,
lisinopril (10mg or 20mg) was shown to have beneficial effects on the progression of
retinopathy in patients with type I diabetes. Chaturvedi, et al., "The effect of the ACE
inhibitor lisinopril on retinopathy in normotensive people with insulin dependent
35 diabetes mellitus - findings from EUCLID, a randomized controlled trial," *The Lancet*,
351, 28-31 (1997).

ACE inhibitors orally because diabetes is a systemic disease with manifestations throughout the body, e.g., the eyes and kidneys.

5

Summary of the Invention

10 The present invention is directed to compositions of ACE inhibitors that can be administered topically to the eye at concentrations to treat ocular manifestations of type I diabetes. Furthermore, if the patient can tolerate effective systemic concentrations of ACE inhibitors, higher concentrations of ACE inhibitors can be administered topically to the eyes, effectively treating not only ocular problems associated with diabetes, but also the neuropathy and/or nephropathy usually occurring in patients with type I diabetes.

Description of Preferred Embodiments

15 The compositions of the present invention contain pharmaceutically effective amounts of at least one ACE inhibitor, typically 0.01 - 10.0 percent by weight (wt.%). The concentration will vary depending on the potency of the ACE inhibitor and whether it is desirable to dose for treatment mainly of ocular tissues or whether systemic dosing is desired for the treatment of ocular tissues and other sites of damage associated with type I diabetes. The compositions are dosed one to four times per day according to the discretion of a skilled clinician.

25 ACE inhibitors and ACE inhibitor prodrugs which can be formulated and used according to the present invention include, but are not limited to captopril, lisinopril, perindopril, enalapril, enalaprilat, SQ 29,852, fosinopril, fosinoprilat, zofenopril, zofenoprilat, and ceronapril.

30 Lisinopril is the preferred ACE inhibitor due to its potency and long half life (greater than twelve hours). Consequently, the concentration at which it is dosed can be lower and its dosing frequency reduced compared to other ACE inhibitors. For treating mainly eye tissues the concentration is about 0.05 to 3.0 wt.%, preferably 0.1 to 1.0 wt.% dosed once or twice a day. For systemic dosing via topical administration, the concentration is about 0.5 to 10.0 wt.%, preferably 1.0 to 3.0 wt.% dosed twice daily.

35

The following compositions are illustrative; they are not limiting.

Ingredient Description	Concentration			
	Solution	Solution	Suspension	Solution
Active				
Lisinopril	1.0%	3.0%	1.0%	5.0%
Polymer				
Carbopol		0.2%		
Eucheuma*			0.6%	
EHEC**				2.0%
Drug Carrier				
Cyclodextrin		5.0%		5.0%
Duolite AP (Ion Exchange Resin)			1.0%	
Preservative				
BAC	0.01%	0.01%		
Polyquad			0.005%	
Cosmocil				0.005%
Chelator				
Edetate sodium			0.005%	
Tonicity Agent	Q. S. to 300 mOsm	Q. S. to 300 mOsm	Q. S. to 300 mOsm	Q. S. to 300 mOsm
Mannitol		4.0%		
Glycerol			3.0%	
NaCl	0.5%			0.2%
Na ₂ SO ₄				0.8%
Buffer				
NaOAc				0.07%
Na ₂ HPO ₄	0.2%			
Tromethamine /Borate			0.5%	
Acid / Base	Q.S. to pH 6 - 7	Q.S. to pH 6 - 7	Q.S. to pH 6 - 7	Q.S. to pH 6 - 7
HCl	0	0	0	0
NaOH	0	0	0	0

- 5 * U.S. Patent Nos. 5,403,841 and 5,212,162
 ** (ethylhydroxyalkylcellulose) U.S. Patent No. 5,681,800

We Claim:

1. A composition for topical ocular administration comprising a pharmaceutically effective amount of an angiotensin-converting enzyme inhibitor.

5

2. The composition of Claim 1 wherein the angiotensin-converting enzyme inhibitor is lisinopril.

3. A method for treating diabetic retinopathy which comprises administering topically to an eye a composition comprising a pharmaceutically effective amount of an angiotensin-converting enzyme inhibitor.

10

4. The method of Claim 3 wherein the angiotensin-converting enzyme inhibitor is lisinopril.

15

5. A method for treating the neuropathy, retinopathy, and nephropathy associated with diabetes which comprises administering topically to an eye a composition comprising a pharmaceutically effective amount of an angiotensin-converting enzyme inhibitor.

20

6. The method of Claim 5 wherein the angiotensin-converting enzyme inhibitor is lisinopril.

INTERNATIONAL SEARCH REPORT

Int. l. Application No

PCT/US 98/27183

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K31/00 A61K31/40 A61K38/55

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	PATENT ABSTRACTS OF JAPAN vol. 098, no. 013, 30 November 1998 & JP 10 218792 A (SANTEN PHARMACEUT CO LTD), 18 August 1998 see abstract ---	1, 2
X	EP 0 220 107 A (MERCK & CO INC) 29 April 1987 see abstract see page 4, line 49 - line 57; claims 1, 3, 6, 7; example 3 ---	1, 2
X	EP 0 114 333 A (SCHERING CORP) 1 August 1984 see the whole document --- -/--	1



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

20 May 1999

Date of mailing of the international search report

07/06/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Hoff, P

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 099 239 A (SQUIBB & SONS INC) 25 January 1984 see abstract see claims; examples 8-13,16 ---	1
X	WATKINS, ROBERT W. ET AL: "Topical ocular hypotensive effects of the novel angiotensin-converting enzyme inhibitor SCH 33861 in conscious rabbits" J. OCUL. PHARMACOL. (1987), 3(4), 295-307 CODEN: JOPHER;ISSN: 8756-3320, XP002103254 see the whole document ---	1
X	CHATURVEDI, NISH ET AL: "Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes" LANCET (1998), 351(9095), 28-31 CODEN: LANCAO;ISSN: 0140-6736, XP002103255 cited in the application see the whole document ---	3-6
X	GOA, KAREN L. ET AL: "Lisinopril: a review of its pharmacology and use in the management of the complications of diabetes mellitus" DRUGS (1997), 53(6), 1081-1105 CODEN: DRUGAY;ISSN: 0012-6667, XP002103256 see the whole document ---	3-6
X	WATKINS R W ET AL: "Systemic effects resulting from topical ocular administration of SCH 33861, a novel ACE inhibitor ocular hypotensive agent." JOURNAL OF OCULAR PHARMACOLOGY, (1988 SUMMER) 4 (2) 93-100. JOURNAL CODE: IRG. ISSN: 8756-3320., XP002103257 United States	1
Y	see abstract see page 99, paragraph 3 ---	3,5
Y	OTTLECH A ET AL: "Captopril ameliorates the decreased Na ⁺ ,K ⁺ -ATPase activity in the retina of streptozotocin-induced diabetic rats." INVESTIGATIVE OPHTHALMOLOGY AND VISUAL SCIENCE, (1996 JUL) 37 (8) 1633-41 JOURNAL CODE: GWI. ISSN: 0146-0404., XP002103258 United States see the whole document -----	3,5

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 98/27183

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 0220107	A	29-04-1987	US 4656188 A	07-04-1987
			JP 62103027 A	13-05-1987
<hr/>				
EP 0114333	A	01-08-1984	AT 55911 T	15-09-1990
			JP 1419834 C	14-01-1988
			JP 59130816 A	27-07-1984
			JP 62025645 B	04-06-1987
			US 4826812 A	02-05-1989
<hr/>				
EP 0099239	A	25-01-1984	US 4442089 A	10-04-1984
			JP 59021614 A	03-02-1984
<hr/>				

THIS PAGE BLANK (USPTO)